EP2861619A4 - Menschliches bispezifisches antikörper-molekül egfrvii - Google Patents

Menschliches bispezifisches antikörper-molekül egfrvii

Info

Publication number
EP2861619A4
EP2861619A4 EP13800038.5A EP13800038A EP2861619A4 EP 2861619 A4 EP2861619 A4 EP 2861619A4 EP 13800038 A EP13800038 A EP 13800038A EP 2861619 A4 EP2861619 A4 EP 2861619A4
Authority
EP
European Patent Office
Prior art keywords
egfrviii antibody
human bispecific
engaging molecules
antibody engaging
bispecific egfrviii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP13800038.5A
Other languages
English (en)
French (fr)
Other versions
EP2861619A1 (de
Inventor
Darell Bigner
Chien-Tsun Kuan
John SAMPSON
Bryan Choi
Ira H Pastan
Patrick C Gedeon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
US Government
Duke University
Original Assignee
US Department of Health and Human Services
US Government
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services, US Government, Duke University filed Critical US Department of Health and Human Services
Publication of EP2861619A1 publication Critical patent/EP2861619A1/de
Publication of EP2861619A4 publication Critical patent/EP2861619A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP13800038.5A 2012-06-07 2013-06-07 Menschliches bispezifisches antikörper-molekül egfrvii Withdrawn EP2861619A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261656717P 2012-06-07 2012-06-07
PCT/US2013/044672 WO2013185010A1 (en) 2012-06-07 2013-06-07 HUMAN BISPECIFIC EGFRvIII ANTIBODY ENGAGING MOLECULES

Publications (2)

Publication Number Publication Date
EP2861619A1 EP2861619A1 (de) 2015-04-22
EP2861619A4 true EP2861619A4 (de) 2016-01-27

Family

ID=49712665

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13800038.5A Withdrawn EP2861619A4 (de) 2012-06-07 2013-06-07 Menschliches bispezifisches antikörper-molekül egfrvii

Country Status (6)

Country Link
US (1) US9676858B2 (de)
EP (1) EP2861619A4 (de)
JP (1) JP6154895B2 (de)
AU (1) AU2013271428B2 (de)
CA (1) CA2876133C (de)
WO (1) WO2013185010A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2718399T3 (es) 2013-07-09 2019-07-01 Univ Duke Moléculas que se acoplan a anticuerpos EGFRVIII biespecíficas humanas
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
UA125252C2 (uk) 2016-01-21 2022-02-09 Пфайзер Інк. Химерний антигенний рецептор, що націлений на варіант iii рецептора епідермального фактора росту
CN109219618B (zh) * 2016-01-21 2022-08-09 辉瑞大药厂 针对表皮生长因子受体变体iii和cd3的单特异性和双特异性抗体及其用途
EA039859B1 (ru) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
CN109475911B (zh) * 2016-07-15 2021-06-25 杰富意钢铁株式会社 冲压成型用的金属板及其制造方法、和冲压件制造方法
WO2018140845A2 (en) * 2017-01-27 2018-08-02 Duke University Bi-specific antibodies to cd64 and a disease antigen
EP3833390A4 (de) * 2018-08-09 2022-05-11 Duke University Verbesserte abgabe von medikamenten und anderen verbindungen an das gehirn und anderes gewebe

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005012479A2 (en) * 2003-06-27 2005-02-10 Abgenix, Inc Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
WO2005118635A2 (en) * 2004-06-03 2005-12-15 Novimmune S.A. Anti-cd3 antibodies and methods of use thereof
WO2008119566A2 (en) * 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific bispecific binders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2224243A1 (de) * 2003-09-12 2010-09-01 Life Technologies Corporation Identifizierung von Modulatoren der enzymatischen Aktivität
NZ546173A (en) * 2003-10-16 2009-04-30 Micromet Ag Multispecific deimmunized CD3-binders
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
EP1711199A2 (de) * 2004-01-05 2006-10-18 Biotech Studio, LLC Biotherapeutika, diagnostika und forschungsreagenzien
CN101495512A (zh) * 2004-04-22 2009-07-29 弗劳恩农场主协会应用研究开发E.V. 特异地结合链球菌表面抗原ⅰ/ⅱ的双价抗体及其使用方法
TW200738750A (en) * 2005-12-06 2007-10-16 Domantis Ltd Ligands and methods of use therefor
JP2010524851A (ja) * 2007-04-03 2010-07-22 マイクロメット アーゲー 種間特異的結合ドメイン
JP5398703B2 (ja) * 2007-05-14 2014-01-29 バイオジェン・アイデック・エムエイ・インコーポレイテッド 一本鎖ＦＣ（ＳｃＦｃ）領域、それを含む結合ポリペプチド、およびそれに関連する方法
WO2009030239A1 (en) * 2007-09-06 2009-03-12 Genmab A/S Novel methods and antibodies for treating cancer
US9249217B2 (en) * 2010-12-03 2016-02-02 Secretary, DHHS Bispecific EGFRvIII x CD3 antibody engaging molecules

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005012479A2 (en) * 2003-06-27 2005-02-10 Abgenix, Inc Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
WO2005118635A2 (en) * 2004-06-03 2005-12-15 Novimmune S.A. Anti-cd3 antibodies and methods of use thereof
WO2008119566A2 (en) * 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific bispecific binders

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LUM H E ET AL: "Preclinical studies comparing different bispecific antibodies for redirecting T cell cytotoxicity to extracellular antigens on prostate carcinomas", ANTICANCER RESEARCH - INTERNATIONAL JOURNAL OF CANCER RESEARCH AND TREATMENT, INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH, GR, vol. 25, no. 1A, 1 January 2005 (2005-01-01), pages 43 - 52, XP008066875, ISSN: 0250-7005 *
LUM L G ET AL: "The new face of bispecific antibodies: targeting cancer and much more", EXPERIMENTAL HEMATOLOGY, ELSEVIER INC, US, vol. 34, no. 1, 1 January 2006 (2006-01-01), pages 1 - 6, XP027879478, ISSN: 0301-472X, [retrieved on 20060101] *
See also references of WO2013185010A1 *

Also Published As

Publication number Publication date
JP2015521587A (ja) 2015-07-30
EP2861619A1 (de) 2015-04-22
CA2876133C (en) 2017-06-06
CA2876133A1 (en) 2013-12-12
US9676858B2 (en) 2017-06-13
US20150132306A1 (en) 2015-05-14
WO2013185010A1 (en) 2013-12-12
AU2013271428B2 (en) 2016-08-04
JP6154895B2 (ja) 2017-06-28
AU2013271428A1 (en) 2015-01-22

Similar Documents

Publication Publication Date Title
HRP20181355T1 (hr) Bispecifične molekule koje se vežu na antigen
HK1216538A1 (zh) 人類微管相關蛋白抗體
HK1202563A1 (en) Sequence symmetric modified igg4 bispecific antibodies igg4
EP2922874A4 (de) Bispezifische antikörper
HK1202565A1 (en) Sequence symmetric modified igg4 bispecific antibodies igg4
IL232420A0 (en) Antibody molecules with specificity for human 40ox
EP2861619A4 (de) Menschliches bispezifisches antikörper-molekül egfrvii
PL3019532T3 (pl) Ludzkie bispecyficzne cząsteczki angażujące przeciwciało egfrviii
ZA201407272B (en) Anti-baff-anti-il-17 bispecific antibodies
GB201219487D0 (en) Anti-S100A4 antibody molecules and their uses

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20141219

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20160107

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/28 20060101AFI20151222BHEP

Ipc: A61P 35/00 20060101ALI20151222BHEP

Ipc: A61K 39/395 20060101ALI20151222BHEP

Ipc: C12N 15/13 20060101ALI20151222BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20170601

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20171012